TY - JOUR
T1 - Association of study design features and treatment effects in trials of chronic medical conditions
T2 - a meta-epidemiological study
AU - Wang, Zhen
AU - Alahdab, Fares
AU - Farah, Magdoleen
AU - Seisa, Mohamed
AU - Firwana, Mohammed
AU - Rajjoub, Rami
AU - Saadi, Samer
AU - Jawaid, Tabinda
AU - Nayfeh, Tarek
AU - Murad, Mohammad Hassan
N1 - © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Objectives To evaluate the association of study design features and treatment effects in randomised controlled trials (RCTs) evaluating therapies for individuals with chronic medical conditions. Design Meta-epidemiological study. Setting RCTs from meta-analyses published in the 10 general medical journals with the highest impact factor published between 1 January 2007 and 10 June 2019 and evaluated a drug, procedure or device treatment of chronic medical conditions. Main outcome measures The association between trial design features and the effect size, reporting a ratio of ORs (ROR) and 95% confidence interval (CI). Results We included 1098 trials from 86 meta-analyses. The most common outcome in the trials was mortality (52%), followed by disease progression (16%) and adverse events (12%). Lack of blinding of patients and study personnel was associated with a larger treatment effect (ROR 1.12; 95% CI 1.00 to 1.25). There was no statistically significant association with random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data, whether trials were stopped early, study funding, type of interventions or with type of outcomes (objective vs subjective). Conclusion The meta-epidemiological study did not demonstrate a clear pattern of association between risk of bias indicators and treatment effects in RCTs in chronic medical conditions. The unpredictability of the direction of bias emphasises the need to make every attempt to adhere to blinding, allocation concealment and reduce attrition bias. Trial registration number Not applicable.
AB - Objectives To evaluate the association of study design features and treatment effects in randomised controlled trials (RCTs) evaluating therapies for individuals with chronic medical conditions. Design Meta-epidemiological study. Setting RCTs from meta-analyses published in the 10 general medical journals with the highest impact factor published between 1 January 2007 and 10 June 2019 and evaluated a drug, procedure or device treatment of chronic medical conditions. Main outcome measures The association between trial design features and the effect size, reporting a ratio of ORs (ROR) and 95% confidence interval (CI). Results We included 1098 trials from 86 meta-analyses. The most common outcome in the trials was mortality (52%), followed by disease progression (16%) and adverse events (12%). Lack of blinding of patients and study personnel was associated with a larger treatment effect (ROR 1.12; 95% CI 1.00 to 1.25). There was no statistically significant association with random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data, whether trials were stopped early, study funding, type of interventions or with type of outcomes (objective vs subjective). Conclusion The meta-epidemiological study did not demonstrate a clear pattern of association between risk of bias indicators and treatment effects in RCTs in chronic medical conditions. The unpredictability of the direction of bias emphasises the need to make every attempt to adhere to blinding, allocation concealment and reduce attrition bias. Trial registration number Not applicable.
KW - Bias
KW - Epidemiologic Studies
KW - Humans
KW - Research Design
UR - http://www.scopus.com/inward/record.url?scp=85118669360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118669360&partnerID=8YFLogxK
U2 - 10.1136/bmjebm-2021-111667
DO - 10.1136/bmjebm-2021-111667
M3 - Article
C2 - 34210673
AN - SCOPUS:85118669360
SN - 2515-446X
VL - 27
SP - 104
EP - 108
JO - BMJ Evidence-Based Medicine
JF - BMJ Evidence-Based Medicine
IS - 2
ER -